A
An Vandebosch
Researcher at Janssen Pharmaceutica
Publications - 34
Citations - 2547
An Vandebosch is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Randomized controlled trial & Vaccine efficacy. The author has an hindex of 11, co-authored 25 publications receiving 944 citations.
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Jerald C. Sadoff,Glenda Gray,An Vandebosch,Vicky Cardenas,Georgi Shukarev,Beatriz Grinsztejn,Paul A. Goepfert,Carla Truyers,Hein Fennema,Bart Spiessens,Kim Offergeld,Gert Scheper,Kimberly L Taylor,Merlin L. Robb,John J. Treanor,Dan H. Barouch,Jeffrey J. Stoddard,Martin Ryser,Mary A. Marovich,Kathleen M. Neuzil,Lawrence Corey,Nancy Cauwenberghs,Tamzin Tanner,Karin Hardt,Javier Ruiz-Guiñazú,Mathieu Le Gars,Hanneke Schuitemaker,Johan Van Hoof,Frank Struyf,Macaya Douoguih +29 more
TL;DR: A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe–critical disease, including hospitalization and death, in an international, randomized, double-blind, placebo-controlled, phase 3 trial.
Journal ArticleDOI
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
Damayanthi Devineni,Linda Morrow,Marcus Hompesch,Donna Skee,An Vandebosch,Joseph Murphy,K. Ways,S. Schwartz +7 more
TL;DR: Canagliflozin is a sodium‐glucose co‐transporter 2 (SGLT2) inhibitor that is being investigated for the treatment of type 2 diabetes mellitus (T2DM).
Journal ArticleDOI
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
Jerald C. Sadoff,G. Gray,An Vandebosch,Vicky Cárdenas,Georgi Shukarev,Beatriz Grinsztejn,Paul A. Goepfert,Carla Truyers,Ilse Van Dromme,Bart Spiessens,Johan Vingerhoets,Jerome Custers,Gert Scheper,Merlin L. Robb,John T. Treanor,Martin F. Ryser,Dan H. Barouch,Edith Swann,Mary A. Marovich,Kathleen M. Neuzil,Lawrence Corey,Jeffrey Lynn Stoddard,Karin Hardt,Javier Ruiz-Guiñazú,Mathieu Le Gars,Hanneke Schuitemaker,Jan Van Hoof,Frank Struyf,Macaya Douoguih +28 more
TL;DR: A single dose of Ad26.COV2.S was associated with mainly mild-to-moderate adverse events, and no new safety concerns were identified; higher protection was observed against severe Covid-19, medical intervention, and death than against other end points and lasted for 6 months or longer.
Journal ArticleDOI
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials.
Devan V. Mehrotra,Holly Janes,Thomas R. Fleming,Paula W. Annunziato,Kathleen M. Neuzil,Lindsay N. Carpp,David Benkeser,Elizabeth R. Brown,Marco Carone,Iksung Cho,Deborah Donnell,Michael P. Fay,Youyi Fong,Shu Han,Ian Hirsch,Ying Huang,Yunda Huang,Ollivier Hyrien,Michal Juraska,Alex Luedtke,Martha Nason,An Vandebosch,Honghong Zhou,Myron S. Cohen,Lawrence Corey,Jonathan Hartzel,Dean Follmann,Peter B. Gilbert +27 more
TL;DR: A group of industry, government, and academic researchers discuss pragmatic issues in the choice and interpretation of clinical endpoints for evaluating efficacy in COVID-19 vaccine trials.
Journal ArticleDOI
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
Ramon Roozendaal,Jenny Hendriks,Thierry Van Effelterre,Bart Spiessens,Liesbeth Dekking,Laura Solforosi,Dominika N. Czapska-Casey,Viki Bockstal,Jeroen N Stoop,Daniel Splinter,Sarah Janssen,Ben Van Baelen,Nadia Verbruggen,Nadia Verbruggen,Jan Serroyen,Eline Dekeyster,Ariane Volkmann,Yvonne Wollmann,Ricardo Carrion,Luis D. Giavedoni,Cynthia Robinson,Maarten Leyssen,Macaya Douoguih,Kerstin Luhn,Maria Grazia Pau,Jerry Sadoff,An Vandebosch,Hanneke Schuitemaker,Roland Zahn,Benoit Callendret +29 more
TL;DR: The human vaccine-elicited EBOV GP-binding antibody levels are in a range associated with significant protection against mortality in NHP, which indicates that the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in humans will likely provide protection against E BOV disease.